Brought to you by 
GPC Biotech licenses bryostatin-1 from Arizona State
26 Nov 2002
Executive Summary
Genomics company GPC Biotech (oncology, immunology, and infectious disease therapeutics) licensed Phase II cancer compound bryostatin-1 from Arizona State University.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com